Danon disease

Jump to navigation Jump to search
Danon disease
OMIM 300257
MeSH D052120

WikiDoc Resources for Danon disease


Most recent articles on Danon disease

Most cited articles on Danon disease

Review articles on Danon disease

Articles on Danon disease in N Eng J Med, Lancet, BMJ


Powerpoint slides on Danon disease

Images of Danon disease

Photos of Danon disease

Podcasts & MP3s on Danon disease

Videos on Danon disease

Evidence Based Medicine

Cochrane Collaboration on Danon disease

Bandolier on Danon disease

TRIP on Danon disease

Clinical Trials

Ongoing Trials on Danon disease at Clinical Trials.gov

Trial results on Danon disease

Clinical Trials on Danon disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Danon disease

NICE Guidance on Danon disease


FDA on Danon disease

CDC on Danon disease


Books on Danon disease


Danon disease in the news

Be alerted to news on Danon disease

News trends on Danon disease


Blogs on Danon disease


Definitions of Danon disease

Patient Resources / Community

Patient resources on Danon disease

Discussion groups on Danon disease

Patient Handouts on Danon disease

Directions to Hospitals Treating Danon disease

Risk calculators and risk factors for Danon disease

Healthcare Provider Resources

Symptoms of Danon disease

Causes & Risk Factors for Danon disease

Diagnostic studies for Danon disease

Treatment of Danon disease

Continuing Medical Education (CME)

CME Programs on Danon disease


Danon disease en Espanol

Danon disease en Francais


Danon disease in the Marketplace

Patents on Danon disease

Experimental / Informatics

List of terms related to Danon disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Danon disease (or glycogen storage disease Type IIb) is a lysosomal storage disease that was first characterized in 1981 by Dr. M.J. Danon.[1] Danon Disease is an X-linked dominant disorder that predominantly affects cardiac muscle. It affects both males and females, although males tend to see the majority of mental retardation and muscle weakness.

A mutated gene that codes a protein called LAMP2[2] causes Danon Disease. LAMP2 protein is a glycoprotein molecule comprised of a carbohydrate and a protein. It is typically found on the membrane of the lysosome. LAMP2 is deficient in individuals affected by Danon Disease but it is unknown how this deficiency disrupts the function of the lysosome.


Muscle weakness, heart disease, and mental retardation are three main symptoms associated with this disorder. Signs of muscle weakness and heart disease begin to manifest in early childhood or adolescence. Some affected individuals are unable to walk as muscular complications progress. Heart disease associated with Danon Disease involves heart arrhythmias and cardiomyopathy, or severe heart muscle disease. Visual problems may also occur.

In females, the symptoms of Danon Disease are less severe and manifest later than they do in affected males. Muscle weakness is present, but commonly less debilitating than it is in males. Heart disease, which may occur, will manifest in adulthood. Symptoms may include visual problems.

Inheritance Pattern

Danon Disease is an X-linked dominant disorder. It selectively and more often affects boys, since males have only one X chromosome. Females have two X chromosomes and therefore have an extra X to protect them from disorders of this inheritance nature, but cases of Danon Disease afflicting females have been reported. Danon Disease also commonly affects males more severely than it does females. Boys often develop symptoms in childhood or in adolescence. Symptoms may not appear in females until adolescence or adulthood.

Life Expectancy

Life expectancy for Danon Disease is 30 years of age or younger and result from cardiac failure.

Diagnosis and Testing

Several mutations have been found on the LAMP2 gene, and genetic analysis is a necessary diagnostic tool for confirming or disconfirming a diagnosis of Danon Disease. Prenatal genetic screening is available. A muscle tissue biopsy, which reveals large vacuoles containing elevated levels of glycogen, a kind of a sugar, used in conjunction with genetic screening may confirm a diagnosis. Cardiac MRI is also used to diagnose heart disease.

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance[3] (DO NOT EDIT)

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including

  • evaluation of dilated cardiomyopathy in the setting of normal coronary arteries,
  • patients with positive cardiac enzymes without obstructive atherosclerosis on angiography,
  • patients suspected of amyloidosis or other infiltrative diseases,
  • hypertrophic cardiomyopathy,
  • arrhythmogenic right ventricular dysplasia, or
  • syncope or ventricular arrhythmia.


Medications to treat the heart disease are often prescribed and in severe cases, a heart transplant is often needed. Supportive treatment, such as physical therapy, may improve muscle strength and balance.

External Links


  1. Danon MJ, Oh SJ, DiMauro S; et al. (1981). "Lysosomal glycogen storage disease with normal acid maltase". Neurology. 31 (1): 51–7. PMID 6450334. Unknown parameter |month= ignored (help)
  2. Lobrinus JA, Schorderet DF, Payot M; et al. (2005). "Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease)". Neuromuscular disorders : NMD. 15 (4): 293–8. doi:10.1016/j.nmd.2004.12.007. PMID 15792868. Unknown parameter |month= ignored (help)
  3. American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.

Template:X-linked disorders

Template:WH Template:WS